// changes done below on July 01 2024 // till here on July 01 2024

ADC Contract Manufacturing Market Revenue to cross US$ 6.8 billion by 2035

Published: April 2024


According to a recently published report by Roots Analysis, the growing demand for ADC therapeutics and the complexities associated with their manufacturing are driving the ADC contract manufacturing market growth.

ADC Contract Manufacturing Industry Overview

The global ADC contract manufacturing market size was estimated to grow at an annualized growth rate of 14% during the forecast period 2023-2035 and is expected to reach over USD 6.8 billion by 2035.

The manufacturing of antibody drug conjugates is fraught with several challenges, including special safety and analytical considerations, high capital investments in manufacturing facilities and demand for extensive training programs to assist the individuals who are involved in such operations. In order to deal with the aforementioned challenges, a number of pharmaceutical companies prefer to outsource their ADC manufacturing and bioconjugation requirements to specialized contract service providers. Further, owing to the need for facilities that strictly follow the cGMP criteria and guidelines for standard bio-molecule production, coupled with the requirement for the manufacturing of multiple ADC components at the same facility to mitigate challenges related to scale-up and technology transfer, the reliability on one-stop shop ADC contract manufacturers is anticipated to grow significantly. Therefore, the ADC contract manufacturing market is anticipated to evolve rapidly in the coming decade.

Browse 190+ figures and 230+ market data tables spread across 430+ pages and detailed Table of Content on “ADC Contract Manufacturing Market (6th Edition): Industry Trends and Global Forecasts, till 2035 by Stage of Development, Process Component, Target Indication, Antibody Generation, Antibody Origin, Antibody Isotype, Type of Payload, Type of Linker and Key Geographical Regions” here: https://www.rootsanalysis.com/reports/adc-contract-manufacturing-market/218.html

Market Drivers

Several factors are propelling the growth of the ADC contract manufacturing market. The rich pipeline of ADC therapeutics is an important factor that is expected to impact the future growth of the ADC contract manufacturing industry. The presence of multiple late-stage candidates indicates several short and mid-term opportunities for the commercial ADC therapeutics market. Moreover, owing to the healthy early-stage pipeline, growth in this domain is expected to continue in the long-term as well. This will, in turn offer more sustained business opportunities to the contract manufacturers in this domain. Further, the manufacturing requirement for multiple ADC components has accentuated the need for one-stop shop ADC manufacturing contract service providers, having the required ADC development and manufacturing capabilities for all the components at various scale of operation. Hence, the ADC contract manufacturing market is poised for substantial growth.

Market Restraints

Market restraints are the factors or conditions that can impede the growth and progress of a market. While the ADC contract manufacturing market is experiencing substantial growth, it is not without challenges. One of the primary restraints is the failure of more than 90 clinical stage product candidates, owing to the concerns related to limited efficacy, associated toxicity and fatal infections, leading to unused / idle manufacturing capacity. Moreover, considering the fact that there are no defined regulatory considerations for ADCs, therefore, ADC contract manufacturers are required to follow stringent regulatory guidelines which are well defined for both small and large molecules. It is worth noting that the process of filing is relatively more complex for ADCs, as it requires separate descriptions for the development and manufacturing process of antibody, payload, linker and conjugated drug substances, posing as a restraint for the overall market growth.

Growth Factors

Despite the challenges, several growth factors continue to drive the ADC contract manufacturing market forward. With the rapidly increasing demand for ADC therapeutics and the higher cost of manufacturing in developed countries, several ADC contract manufacturers are exploring the option to carry out their manufacturing operations in the offshore locations, considering  the low cost of labor in developing countries. As a result, companies based China and India, are attracting lucrative business opportunities from sponsors based in developed geographies. Further, the emergence of novel technology platforms is expected to provide an impetus to the overall growth of the ADC market and mitigate the challenges associated with the use of traditional conjugation approaches.

ADC Contract Manufacturing Market Segments

Based on stage of development, the market is segmented into Phase I, Phase II, Phase III and Commercial.

  • The commercial segment led the ADC contract manufacturing market, capturing the largest revenue share of over 70.0% in 2023.
  • The commercial segment is anticipated to show the highest annual growth rate of 16% during the forecast period.

Based on process component, the market is segmented into Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish.

  • The antibody component led the ADC contract manufacturing market, capturing the largest revenue share of 40.0% in 2023.
  • Owing to the intricacies and complexities associated with the manufacturing of antibodies, this trend is expected to remain same during the forecast period.

Based on target indication, the market is segmented into Solid Tumors, Hematological Tumors and other tumors.

  • The solid tumors segment led the ADC contract manufacturing market, capturing the largest revenue share of over 50.0% in 2023.
  • The hematological tumors segment is anticipated to show an annual growth rate of 13% during the forecast period.

Based on antibody generation, the market is segmented into Second Generation, Third Generation, Fourth Generation and Next Generation.

  • The third generation segment led the ADC contract manufacturing market for antibody component, capturing the largest revenue share of 45.0% in 2023.
  • The fourth generation and next generation segments are anticipated to show an annual growth rate of 17%, each during the forecast period.

Based on antibody origin, the market is segmented into Human, Chimeric, Murine and other origins.

  • The human origin segment led the ADC contract manufacturing market for antibody component, capturing the largest revenue share of 60.0% in 2023.
  • The chimeric origin segment is anticipated to show an annual growth rate of 16% during the forecast period.

Based on antibody isotype, the market is segmented into IgG1, IgG4 and other isotypes.

  • The IgG1 isotype segment led the ADC contract manufacturing market for antibody component, capturing the largest revenue share of nearly 95.0% in 2023.
  • The IgG4 isotype segment is anticipated to show an annual growth rate of 17% during the forecast period.

Based on type of payload, the market is segmented into Auristatin, Camptothecin, DNA Topoisomerase I Inhibitor, Maytansinoid and others.

  • The camptothecin payload segment led the ADC contract manufacturing market for HPAPI / cytotoxic payload component, capturing the largest revenue share of 42.0% in 2023.
  • The maytansinoid payload segment is anticipated to show an annual growth rate of 17% during the forecast period.

Based on type of linker, the market is segmented into Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and other linkers.

  • The maleimide linker segment led the ADC contract manufacturing market for conjugation / linker component, capturing the largest revenue share of 28.0% in 2023.
  • The maleimide linker segment is anticipated to show an annual growth rate of 16% during the forecast period.

Based on key geographical regions, the market is segmented into North America, Europe, Asia Pacific and Rest of the World

  • North America dominated the ADC contract manufacturing market and accounted for the largest revenue share of about 46.0% in 2023.
  • In Europe, the ADC contract manufacturing market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The ADC contract manufacturing market report also includes detailed profiles of key players (listed below) that offer ADC contract manufacturing services:

  • AbbVie Contract Manufacturing
  • Abzena
  • CARBOGEN AMCIS
  • Catalent Pharma Solutions
  • Cerbios-Pharma
  • Formosa Laboratories
  • GBI
  • Lonza
  • MabPlex
  • Millipore Sigma
  • Piramal Pharma Solutions
  • Sterling Pharma Solutions
  • WuXi Biologics

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/adc-contract-manufacturing-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry